About ESMO ESMO is the European Society for Medical Oncology. Representing more than 35,000 oncology professionals in 172 countries, ESMO is a reference for oncology education and information.

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announces that the company will present updated data from the ...

ESMO24 - Pre-Meeting New Drug Classification OBiS Insights pre-meeting ESMO24 report is based on a review of the 2,960 abstract titles o ...

today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting to be held in Barcelona, Spain from September 13–17, 2024. Title ...

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress Data to be presented on Saturday, September 14 and published ...

today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17 ...

Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024. A Prospective Study of Orelabrutinib plus ...

Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity ...

will be presented by Eisai at the European Society for Medical Oncology (ESMO) Congress 2024, held in Barcelona, Spain from September 13 to 17, 2024. The abstract of the study has been released today.

About Renovaro Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted ...

CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 ...